On the stock market since 2016, it operates in the world of health and science. It has 71 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
Sales run at $21.1M a year. A small number, but proof the product has real buyers.
There is $8.6M in the vault; even if every debt were paid off, $8.2M would remain.
A loss of $92K against $21.1M in annual sales.
The stock sits at $0.56. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, CRRTF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CRRTF is a high-risk stock — not yet profitable, and its future rides on its product catching on.